Covalon Announces Publication of Impactful VALGuard® Line Guard Clinical Study Demonstrating Significant Reduction in Central Line-Associated Blood Stream Infections (CLABSIs)
COV(COV) MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the publication of results from a peer-reviewed clinical study investigating the use of Covalon’s VALGuard® Vascular Access Line Guard in the Journal of the Association for Vascular Access (JAVA). Conducted at the Children’s Hospital at Montefiore, a nationally ranked U.S. pediatric hospital, the study, titled “Evaluat
September 16, 2025Clinical Trials
Read more →